Literature DB >> 31980600

African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxin.

Kumar Sachin Singh1, Julia I-Ju Leu2, Thibaut Barnoud3, Prashanthi Vonteddu1, Keerthana Gnanapradeepan3,4, Cindy Lin5, Qin Liu3, James C Barton6, Andrew V Kossenkov7, Donna L George8, Maureen E Murphy9, Farokh Dotiwala10.   

Abstract

A variant at amino acid 47 in human TP53 exists predominantly in individuals of African descent. P47S human and mouse cells show increased cancer risk due to defective ferroptosis. Here, we show that this ferroptotic defect causes iron accumulation in P47S macrophages. This high iron content alters macrophage cytokine profiles, leads to higher arginase level and activity, and decreased nitric oxide synthase activity. This leads to more productive intracellular bacterial infections but is protective against malarial toxin hemozoin. Proteomics of macrophages reveal decreased liver X receptor (LXR) activation, inflammation and antibacterial defense in P47S macrophages. Both iron chelators and LXR agonists improve the response of P47S mice to bacterial infection. African Americans with elevated saturated transferrin and serum ferritin show higher prevalence of the P47S variant (OR = 1.68 (95%CI 1.07-2.65) p = 0.023), suggestive of its role in iron accumulation in humans. This altered macrophage phenotype may confer an advantage in malaria-endemic sub-Saharan Africa.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31980600      PMCID: PMC6981190          DOI: 10.1038/s41467-019-14151-9

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  38 in total

1.  [Results of radiotherapy of esophageal cancer].

Authors:  K Matsuki; K Koga; K Nishikawa; H Ebihara; S Futami; K Watanabe
Journal:  Nihon Igaku Hoshasen Gakkai Zasshi       Date:  1988-05-25

2.  [Certain differential-diagnostic criteria of involutional and vascular depression].

Authors:  A V Smykov
Journal:  Vrach Delo       Date:  1974

3.  [Tests for infectious mononucleosis and malignant lymphoreticulopathies].

Authors:  A S Pinto
Journal:  Arq Patol       Date:  1973-04

4.  [Case of intrauterine rupture of Lippes loop].

Authors:  M Blaziak; B Liber
Journal:  Wiad Lek       Date:  1973-05-01

5.  [Postoperative development of function in patients with bronchial carcinoma following lung resection: long term prognosis].

Authors:  M Navrátil; Z Koval; J Lichtenberg; H Mostecký
Journal:  Pneumonologie       Date:  1972

6.  The physician-patient relationship: the art and science of communication.

Authors:  H L Hirsh
Journal:  Med Law       Date:  1986

7.  The aetiology of urethral discharge in men.

Authors:  K B Lim; B A Ali; W K Cheong; H C Kwok; H C Lau; M M Seah; E O Lui
Journal:  Singapore Med J       Date:  1985-06       Impact factor: 1.858

8.  Ferroptosis: an iron-dependent form of nonapoptotic cell death.

Authors:  Scott J Dixon; Kathryn M Lemberg; Michael R Lamprecht; Rachid Skouta; Eleina M Zaitsev; Caroline E Gleason; Darpan N Patel; Andras J Bauer; Alexandra M Cantley; Wan Seok Yang; Barclay Morrison; Brent R Stockwell
Journal:  Cell       Date:  2012-05-25       Impact factor: 41.582

9.  Developmental origins of moral masochism: a failure-to-thrive toddler's interactions with mother.

Authors:  C Haynes-Seman
Journal:  Child Abuse Negl       Date:  1987

10.  Developmental changes in the interactions of cholinergic and beta-adrenergic agonists on electrophysiologic properties of canine cardiac Purkinje fibers.

Authors:  J P Moak; R F Reder; P Danilo; M R Rosen
Journal:  Pediatr Res       Date:  1986-07       Impact factor: 3.756

View more
  15 in total

1.  Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy.

Authors:  Wenbo Han; Xiaopin Duan; Kaiyuan Ni; Youyou Li; Christina Chan; Wenbin Lin
Journal:  Biomaterials       Date:  2021-12-09       Impact factor: 12.479

Review 2.  Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications.

Authors:  Brent R Stockwell
Journal:  Cell       Date:  2022-07-07       Impact factor: 66.850

Review 3.  The Role of Ferroptosis in Adverse Left Ventricular Remodeling Following Acute Myocardial Infarction.

Authors:  Kyoko Komai; Nicholas K Kawasaki; Jason K Higa; Takashi Matsui
Journal:  Cells       Date:  2022-04-20       Impact factor: 7.666

Review 4.  p53 in ferroptosis regulation: the new weapon for the old guardian.

Authors:  Yanqing Liu; Wei Gu
Journal:  Cell Death Differ       Date:  2022-01-27       Impact factor: 12.067

5.  Functional interplay among thiol-based redox signaling, metabolism, and ferroptosis unveiled by a genetic variant of TP53.

Authors:  Julia I-Ju Leu; Maureen E Murphy; Donna L George
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-14       Impact factor: 11.205

6.  Effect of the p53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer.

Authors:  Cristabelle De Souza; Jill Madden; Devin C Koestler; Dennis Minn; Dennis J Montoya; Kay Minn; Alan G Raetz; Zheng Zhu; Wen-Wu Xiao; Neeki Tahmassebi; Harikumara Reddy; Nina Nelson; Anthony N Karnezis; Jeremy Chien
Journal:  J Natl Cancer Inst       Date:  2021-09-04       Impact factor: 13.506

7.  Ferroptosis in infection, inflammation, and immunity.

Authors:  Xin Chen; Rui Kang; Guido Kroemer; Daolin Tang
Journal:  J Exp Med       Date:  2021-05-12       Impact factor: 14.307

8.  The complexity of p53-mediated metabolic regulation in tumor suppression.

Authors:  Yanqing Liu; Wei Gu
Journal:  Semin Cancer Biol       Date:  2021-03-27       Impact factor: 17.012

Review 9.  The Regulation of Ferroptosis by Tumor Suppressor p53 and its Pathway.

Authors:  Juan Liu; Cen Zhang; Jianming Wang; Wenwei Hu; Zhaohui Feng
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

Review 10.  Shifting the paradigms for tumor suppression: lessons from the p53 field.

Authors:  Thibaut Barnoud; Alexandra Indeglia; Maureen E Murphy
Journal:  Oncogene       Date:  2021-06-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.